Lenalidomide for the treatment of mantle cell lymphoma

Fortunato Morabito, Mamdouh Skafi, Anna Grazia Recchia, Aya Kashkeesh, Musa Hindiyeh, Ali Sabatleen, Lucio Morabito, Hamdi Alijanazreh, Yousef Hamamreh, Massimo Gentile

Research output: Contribution to journalReview article

Abstract

INTRODUCTION: Although a variety of therapeutic schemes for Mantle Cell Lymphoma (MCL) have been attempted, the clinical outcome of patients continues to be unsatisfactory especially among patients with a very high-risk profile and in the relapsed/refractory setting. For this reason, recent clinical trials have explored novel approaches, either by the use of biological agents in chemotherapy-free schedules or by integrating them with chemoimmunotherapy regimens. Areas covered: The efficacy of lenalidomide monotherapy and combination therapy established in clinical studies mainly involving relapsed/refractory MCL is reviewed. The mechanism of action of lenalidomide is also discussed. Furthermore, the current position of lenalidomide in the MCL treatment algorithm is debated. Expert opinion: Lenalidomide demonstrated high efficacy and tolerability in several clinical trials as well as in retrospective real-world reports, even in patients who relapsed or were resistant to bortezomib and ibrutinib. In 2013, lenalidomide was approved by the Food and Drug Administration (FDA) for relapsed/refractory MCL after two prior therapies including at least one prior treatment with bortezomib. However, the potential synergistic anti-neoplastic effects of lenalidomide in combination with other biological agents, i.e. ibrutinib and venetoclax, especially in the management of p53-mutated cases, still remain an open issue.

Original languageEnglish
Pages (from-to)487-494
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number5
DOIs
Publication statusPublished - Apr 2019

    Fingerprint

Keywords

  • Antineoplastic Agents/therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage
  • Bortezomib/administration & dosage
  • Humans
  • Lenalidomide/therapeutic use
  • Lymphoma, Mantle-Cell/drug therapy
  • Pyrazoles/administration & dosage
  • Pyrimidines/administration & dosage
  • Treatment Outcome

Cite this

Morabito, F., Skafi, M., Recchia, A. G., Kashkeesh, A., Hindiyeh, M., Sabatleen, A., Morabito, L., Alijanazreh, H., Hamamreh, Y., & Gentile, M. (2019). Lenalidomide for the treatment of mantle cell lymphoma. Expert Opinion on Pharmacotherapy, 20(5), 487-494. https://doi.org/10.1080/14656566.2018.1561865